1. Home
  2. VRTX

as 08-22-2025 10:36am EST

$
-
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Technology

EDP Services

Nasdaq

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Founded: 1989 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 115.6B IPO Year: 1991
Target Price: $496.76 AVG Volume (30 days): 2.5M
Analyst Decision: Buy Number of Analysts: 24
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 14.07 EPS Growth: N/A
52 Week Low/High: $362.50 - $519.88 Next Earning Date: 08-04-2025
Revenue: $11,418,800,000 Revenue Growth: 10.46%
Revenue Growth (this year): 10.4% Revenue Growth (next year): 10.63%

VRTX Daily Stock ML Predictions

Share on Social Networks: